Roivant Sciences

ROIV

Market cap $11.8B

Roivant Sciences Ltd. (NASDAQ:ROIV ) Bernstein 2nd Annual Global Healthcare Conference September 23, 2025 1:58 PM EDT Company Participants Matthew Gline - CEO & Director Presentation Unknown Analyst I cover U.S. biotech at Bernstein.

Roivant Sciences Ltd. (NASDAQ:ROIV ) Bank of America Global Healthcare Conference 2025 September 24, 2025 5:45 AM EDT Company Participants Matthew Gline - CEO & Director Conference Call Participants Jason Gerberry - BofA Securities, Research Division Presentation Jason Gerberry BofA Securities, Research Division We're at time.

Does Roivant Sciences Ltd. (ROIV) have what it takes to be a top stock pick for momentum investors?

Roivant Sciences Ltd. (NASDAQ:ROIV ) Q1 2024 Earnings Conference Call August 8, 2024 8:00 AM ET Company Participants Stephanie Lee - Investor Relations Matt Gline - Chief Executive Officer Conference Call Participants Allison Bratzel - Piper Sandler Brian Cheng - JPMorgan Dave Risinger - Leerink Partners Dennis Ding - Jefferies Yaron Werber - TD Cowen Louise Chen - Cantor Yatin Suneja - Guggenheim Douglas Tsao - H.C.

Montes Archimedes Acquisition (ROIV) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Roivant Sciences Ltd. - Special Call Company Participants Stephanie Lee Griffin - Chief Operating Officer of Roivant Platforms Matthew Gline - CEO & Director Benjamin Zimmer Conference Call Participants Yuchen Ding - Jefferies LLC, Research Division Lut Ming Cheng - JPMorgan Chase & Co, Research Division Corinne Jenkins - Goldman Sachs Group, Inc., Research Division Yaron Werber - TD Cowen, Research Division Prakhar Agrawal - Cantor Fitzgerald & Co., Research Division Samuel Slutsky - LifeSci Capital, LLC, Research Division Samantha Semenkow - Citigroup Inc., Research Division Yatin Suneja - Guggenheim Securities, LLC, Research Division Douglas Tsao - H.C.

Shares of Roivant Sciences (ROIV 12.14%) are soaring 11.4% higher as of 11:19 a.m. ET on Wednesday.

Roivant Sciences Ltd ROIV and Priovant Therapeutics released results from the Phase 3 VALOR study evaluating brepocitinib in dermatomyositis (DM).

Shares of Roivant Sciences extended their breakout Wednesday, stoked by promising test results in a difficult-to-treat autoimmune disease.

Roivant and partner Priovant Therapeutics said on Wednesday that their experimental drug for a rare disease affecting both skin and muscle health has shown promising results in a late-stage clinical trial.